Browsing Tag
Ulcerative colitis
32 posts
AzurRx BioPharma acquires US biotech company First Wave Bio for $229m
AzurRx BioPharma has signed a stock and cash deal worth $229 million to acquire Florida-based clinical-stage biotech company…
Zydus Cadila secures US FDA approval for Mesalamine Extended-Release Capsules for ulcerative colitis remission maintenance
Zydus Cadila gets US FDA approval for Mesalamine Extended-Release Capsules 0.375g to maintain ulcerative colitis remission, strengthening its US generics portfolio.
Microbiome company Vedanta Biosciences raises $68m in Series D
Vedanta Biosciences, a clinical-stage microbiome company founded by PureTech Health, has raised $68 million in a Series D…
Merck to acquire US biotech company Pandion Therapeutics for $1.8bn
Merck has agreed to acquire Pandion Therapeutics, a Massachusetts-based clinical-stage biotech company, for about $1.85 billion in an…
ExeGi Pharma’s EXE-346 receives FDA orphan drug designation for pouchitis treatment
ExeGi Pharma, a biotechnology company headquartered in Rockville, Maryland, has announced that its live biotherapeutic product (LBP), EXE-346,…
Seres Therapeutics begins Phase 1b trial for SER-301 in active ulcerative colitis
Seres Therapeutics, a prominent US-based biotech company, has announced the commencement of dosing in a Phase 1b clinical…
Bristol Myers Squibb’s Zeposia shows promising results in phase 3 True North trial for ulcerative colitis treatment
Bristol Myers Squibb (BMS) has reported significant success in its phase 3 True North clinical trial, evaluating the…
Allergan to sell brazikumab to AstraZeneca and Zenpep to Nestle
Allergan has agreed to sell IL-23 inhibitor brazikumab to AstraZeneca and gastrointestinal medication Zenpep (pancrelipase) to Nestle in…
Janssen bags Stelara FDA approval for ulcerative colitis treatment
Stelara FDA approval for ulcerative colitis treatment : The Janssen Pharmaceutical Companies of Johnson & Johnson has bagged…
Teva launches generic version of Delzicol delayed-release capsules in US
Israeli pharma company Teva Pharmaceuticals has launched a generic version of Delzicol (mesalamine) 400mg delayed-release capsules in the…